XML 40 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Business Combinations [Abstract]        
Revenue $ 411 $ 435
Net loss (3,311) (3,223) (6,941) (8,051)
Net loss: Non-controlling interest (91) (145) (219) (339)
Net loss attributable to Heat Biologics, Inc. $ (3,220) $ (3,078) $ (6,722) $ (7,712)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.09) $ (0.17) $ (0.21) $ (0.77)